XTX Topco Ltd Invests $297,000 in UroGen Pharma Ltd. (NASDAQ:URGN)

XTX Topco Ltd acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 23,381 shares of the company’s stock, valued at approximately $297,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of URGN. Point72 Asset Management L.P. increased its stake in shares of UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after purchasing an additional 1,337,257 shares in the last quarter. Millennium Management LLC boosted its holdings in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after buying an additional 1,119,019 shares during the period. Cowen AND Company LLC boosted its holdings in UroGen Pharma by 29.1% in the 2nd quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock worth $35,229,000 after buying an additional 472,893 shares during the period. Vestal Point Capital LP bought a new position in UroGen Pharma in the 3rd quarter worth $5,080,000. Finally, Great Point Partners LLC boosted its holdings in UroGen Pharma by 10.9% in the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock worth $48,767,000 after buying an additional 285,714 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $11.33 on Wednesday. The company has a market capitalization of $265.73 million, a price-to-earnings ratio of -3.60 and a beta of 1.06. UroGen Pharma Ltd. has a 52 week low of $10.60 and a 52 week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm has a 50 day moving average of $12.13 and a 200 day moving average of $13.88.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period last year, the firm earned ($0.68) EPS. On average, sell-side analysts predict that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Friday, December 6th. Finally, Guggenheim initiated coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.